FDA Accepts Second IND Application From Evotec and Bristol Myers Squibb, Paving the Way for Phase 1 in 2027
Key Facts
The U.S. Food and Drug Administration has accepted the second IND application submitted under Evotec and Bristol Myers Squibb’s partnership to develop protein degradation drugs, expanding their joint pipeline of drug candidates. Evotec reported the acceptance in an announcement published on November 19, 2026, while Reuters said the second candidate is expected to enter a Phase 1 clinical trial in 2027. Acceptance allows the candidate to move toward clinical testing, but does not mean the trial has already begun. The candidate is a Cereblon-type E3 ligase modulator, according to Reuters. The development comes as the partnership’s first candidate continues its clinical path after entering a Phase 1 trial in March 2026.
Acceptance of the second application marks further progress in an agreement aimed at discovering protein degradation-based treatments and adds another candidate to the joint program. Evotec said in 2025 that acceptance of an IND application represented a “significant scientific and regulatory milestone” and reinforced the strength of the collaboration, according to its statement at the time. The progress brings the second candidate to the threshold of human testing, while its entry into Phase 1 in 2027 remains an announced expectation. The first candidate reached that stage in March 2026 for advanced clear cell renal cell carcinoma. The partnership now comprises one candidate already in clinical testing and another awaiting its expected move into Phase 1 next year.
Evotec announced on March 19, 2026, that Bristol Myers Squibb had begun a Phase 1 clinical study of the first candidate. The study targeted advanced clear cell renal cell carcinoma, a separate program from the second candidate linked to the Cereblon enzyme. Evotec said the study’s start triggered a $10 million milestone payment to the company. The payment shows that the first candidate’s progress into clinical study was tied to a specified consideration under the collaboration terms. Acceptance of the second IND application expands the partnership’s pipeline, while its expected Phase 1 timing remains in 2027.
The expanded partnership dates to an Evotec announcement in 2022, when the company said the agreement included an upfront payment of $200 million and total deal potential of $5 billion. The agreement also included additional performance-based, near-term and program milestone payments, as well as tiered royalties on sales. Acceptance of the second IND application reflects the collaboration’s continued progression from program development into clinical stages, following the start of the first candidate’s trial. But the figures announced in 2022 describe the deal’s total potential and do not represent payments already realized from the current application acceptance. The specified $10 million payment remains tied to the start of the first candidate’s study in March 2026.
The announcement came as Evotec’s results for the first nine months of 2026 showed group revenue falling 13.1% to 465.0 million euros, compared with 535.1 million euros in the same period of 2025. In its financial statement issued on November 5, 2026, the company said nine-month results exceeded market expectations and reaffirmed its full-year guidance. The results place the partnership news in a period of year-on-year revenue decline, despite the company’s statement that results exceeded market expectations. Acceptance of the second application does not change the reported revenue figures for the period, but adds a clinical development to the collaboration portfolio with Bristol Myers Squibb. The next announced clinical step for the second candidate remains its expected entry into a Phase 1 trial in 2027.
In trading, Evotec’s U.S.-listed shares, under the ticker EVO, closed at $1.46 on November 18, 2026, according to EL7 data. The closing session preceded the company’s November 19 announcement that the second IND application had been accepted. A reliable reading of the stock’s high during the November 18 session is not available here, so the confirmed trading figure is limited to the closing price. Reuters described the shares as rising in Frankfurt after news of the application’s acceptance, without specifying the size of the increase in the available evidence. The move combined fresh regulatory news with an expected future step for the second candidate, while the start of a Phase 1 trial remains expected in 2027.